RXi Names Inflammatory Disease as Lead Program; Neurological Disease Slips Off Radar
March 26, 2009
RXi Names Inflammatory Disease as Lead Program; Neurological Disease Slips Off Radar
The company also noted in a filing with the US Securities and Exchange Commission that it continues to seek out industry partnerships after having failed to forge a deal in 2008 as previously anticipated.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- UMMS Team Publishes In Vitro, In Vivo Data on Oral siRNA-Delivery Tech
April 30, 2009 / Gene Silencing News - MDRNA Narrows Pipeline to Focus Exclusively on Liver Cancer, Inks Licensing Deal with Novartis
March 26, 2009 / Gene Silencing News - Lorus Therapeutics and Ohio State U Partner on Nanoparticle Delivery of siRNA Cancer Rx
March 25, 2009 / - Cenix Begins Building In Vivo Research Operations, Developing siRNA Delivery Tech
April 30, 2009 / Gene Silencing News - Strands
March 19, 2009 / Gene Silencing News